While the current management may be very astute at carrying out research and developing potentially great drug/drug platforms, they ARE NOT showing any signs of success when it comes to commercialisation of these products.
Could explain why HQ haven't been able to strike a DEP® Cabazitaxel and DEP® Docetaxel license deal to date - they may not be up to the challenge or perhaps the results perused under an NDA by multiple pharma groups don't stack up ?
How can a company tout consistently over the years that they are in 'confidential commercial negotiations with several potential partners' and come up empty handed year after year ? They claim these negotiations are ongoing in most ASX announcements - here's an example from 2021 off the back of the interim phase 2 DEP® Cabazitaxel clinical trial results
Looking like another week of absolutely nothing coming out of Starpharma again as another Friday is upon us .... not even a further update on AACR 2 days in as some hoped earlier in the week
Poster Session A on Thursday, October 12, from 12:30-4 P.M.
Poster Session B on Friday, October 13, from 12:30-4 P.M
Poster Session C on Saturday, October 14 from 12:30-4 P.M.
- Forums
- ASX - By Stock
- SPL
- Expectations for September
Expectations for September, page-73
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
0.003(3.09%) |
Mkt cap ! $41.73M |
Open | High | Low | Value | Volume |
9.9¢ | 10.5¢ | 9.9¢ | $12.72K | 127.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50204 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 15181 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 50204 | 0.098 |
4 | 865495 | 0.097 |
1 | 50000 | 0.096 |
3 | 176316 | 0.095 |
2 | 110000 | 0.094 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 15181 | 1 |
0.105 | 106678 | 3 |
0.110 | 210058 | 7 |
0.115 | 122327 | 4 |
0.120 | 59907 | 7 |
Last trade - 10.43am 18/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |